Date: 2015-03-11
Type of information: Collaboration agreement
Compound: Cytovir™ CMV
Company: Cell Medica (UK) The Cell Therapy Catapult (UK)
Therapeutic area: Infectious diseases - Transplantation - Cancer - Oncology
Type agreement: collaboration
Action mechanism: cell therapy/cell immunotherapy. Cytovir™ CMV is an individualised immune cell therapy that involves the infusion of immune cells from a donor into an immunosuppressed patient, in order to reconstitute their immunity to Cytomegalovirus (CMV).Cytovir™ CMV is comprised of naturally occurring CMV-specific memory or effector T cells which can be purified from the blood of the original bone marrow donor and transferred to the patient to provide immunity to the virus.
Disease: treatment of CMV reactivation episodes in patients following allogeneic haematopoietic stem cell transplant
Details: * On March 11, 2015, The Cell Therapy Catapult and Cell Medica, leading players in the emerging UK cell therapy industry, announced a collaboration to accelerate NHS adoption of Cell Medica’s Cytovir™ CMV. Cell Medica is a leading UK cellular immunotherapy company while the Cell Therapy Catapult is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth. Cytovir™ CMV is currently available to treat patients in the UK and Germany. In the infectious disease field, Cell Medica is developing Cytovir CMV for the treatment of cytomegalovirus infections and Cytovir ADV for the treatment of adenovirus infections. Both applications are aimed at treating and preventing infections in patients who are profoundly immunosuppressed following a bone marrow transplant. The clinical development of Cytovir CMV has been funded in part by The Wellcome Trust. Two clinical studies, CMV-IMPACT (NCT01077908) and CMV-ACE/ASPECT (NCT01220895) have been recently completed. Both studies evaluate Cytovir™ CMV for the treatment of CMV reactivation episodes in patients following allogeneic haematopoietic stem cell transplant.
Financial terms:
Latest news:
